| abstract |
Disclosed herein is a combination comprising an inhibitor of Src kinase selected from -4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline, -4- (6-chloro-2, 3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl) ethoxy]-5-tetrahydropyran-4-yloxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof, and the cytotoxic agent gemcitabine for use simultaneously, sequentially or separately in the synergistic treatment or prophylaxis of pancreatic cancer. |